Climb Bio, Inc. CLYM EBIT

EBIT at other companies

Bristol-Myers SquibbBMY

$4.09B+130%

AmgenAMGN

$3.51B+32.3%

Vera TherapeuticsVERA

-$125.13M-119%

Kyverna Therapeutics, Inc.KYTX

-$41.37M+12.7%

Cullinan Therapeutics, Inc.CGEM

-$57.25M+24.5%

Artiva Biotherapeutics, Inc.ARTV

-$26.89M-17.9%

FAQ

What is Climb Bio, Inc.'s EBIT?

Climb Bio, Inc. (CLYM) reported EBIT of -$15.21M in Q1 2026.

How has Climb Bio, Inc.'s EBIT changed year-over-year?

Climb Bio, Inc.'s EBIT increased by 33.9% year-over-year, from -$23.02M to -$15.21M.

What is the long-term trend for Climb Bio, Inc.'s EBIT?

Over 4 years (2021 to 2025), Climb Bio, Inc.'s EBIT has grown at a 17.5% compound annual growth rate (CAGR), from -$35.67M to -$67.88M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.